A detailed history of Vanguard Group Inc transactions in Harrow Health, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 1,840,710 shares of HROW stock, worth $84 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,840,710
Previous 1,829,805 0.6%
Holding current value
$84 Million
Previous $24.2 Million 58.84%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$10.0 - $21.64 $109,050 - $235,984
10,905 Added 0.6%
1,840,710 $38.5 Million
Q1 2024

May 10, 2024

BUY
$9.3 - $13.23 $197,652 - $281,177
21,253 Added 1.18%
1,829,805 $24.2 Million
Q4 2023

Feb 14, 2024

BUY
$8.1 - $16.36 $394,251 - $796,290
48,673 Added 2.77%
1,808,552 $20.3 Million
Q3 2023

Nov 14, 2023

BUY
$14.03 - $22.08 $1.34 Million - $2.11 Million
95,389 Added 5.73%
1,759,879 $25.3 Million
Q2 2023

Aug 14, 2023

BUY
$17.37 - $28.08 $4.83 Million - $7.81 Million
278,164 Added 20.06%
1,664,490 $31.7 Million
Q1 2023

May 15, 2023

BUY
$13.84 - $21.46 $2.96 Million - $4.58 Million
213,530 Added 18.21%
1,386,326 $29.3 Million
Q4 2022

Feb 10, 2023

SELL
$10.28 - $14.78 $80,286 - $115,431
-7,810 Reduced 0.66%
1,172,796 $17.3 Million
Q2 2022

Aug 12, 2022

BUY
$5.75 - $7.74 $589,518 - $793,543
102,525 Added 9.51%
1,180,606 $8.59 Million
Q1 2022

May 13, 2022

SELL
$6.77 - $8.66 $47,241 - $60,429
-6,978 Reduced 0.64%
1,078,081 $7.35 Million
Q4 2021

Feb 14, 2022

SELL
$8.5 - $12.0 $12,537 - $17,700
-1,475 Reduced 0.14%
1,085,059 $9.38 Million
Q2 2021

Aug 13, 2021

BUY
$6.68 - $11.07 $7.26 Million - $12 Million
1,086,534 New
1,086,534 $10.1 Million

Others Institutions Holding HROW

About HARROW HEALTH, INC.


  • Ticker HROW
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 27,070,000
  • Market Cap $1.24B
  • Description
  • Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company tha...
More about HROW
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.